Conventional and targeted medical therapies

Cardiology in the Young

Volumn 19, Issue E-SUPP. 1, 2009, Pages 28-34

  Barst, Robyn J ^a,c   Stewart, Duncan ^b  

^a Columbia University ^*  (United States)

^b UNIVERSITY OF OTTAWA   (Canada)

^c NONE   (United States)

Author keywords

Congenital heart disease; Endothelin receptor antagonists; Phosphodiesterase inhibitors; Prostacyclin; Pulmonary arterial hypertension; Pulmonary vasodilators

Indexed keywords

AMBRISENTAN; ANTICOAGULANT AGENT; BERAPROST; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; OXYGEN; PHOSPHODIESTERASE INHIBITOR; PLACEBO; PROSTACYCLIN; SILDENAFIL; SITAXSENTAN; UNIPROST; WARFARIN; ANTIHYPERTENSIVE AGENT; DRUG DERIVATIVE;

ANTICOAGULATION; ARTICLE; BLALOCK HANLON OPERATION; CLINICAL TRIAL; DIARRHEA; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; EISENMENGER COMPLEX; HEART SURGERY; HEMOGLOBINOPATHY; HOT FLUSH; HUMAN; JAW DISEASE; LIVER TOXICITY; MALE INFERTILITY; NAUSEA; OXYGEN THERAPY; PULMONARY HYPERTENSION; RISK REDUCTION; SYNCOPE; TERATOGENICITY; THROMBOEMBOLISM; THROMBOSIS; VASODILATATION; ALGORITHM; CHILD; CONGENITAL HEART MALFORMATION;

ALGORITHMS; ANTIHYPERTENSIVE AGENTS; CHILD; EPOPROSTENOL; HEART DEFECTS, CONGENITAL; HUMANS; HYPERTENSION, PULMONARY;

EID: 68949199475     PISSN: 10479511     EISSN: 14671107     Source Type: Journal    
DOI: 10.1017/S1047951109003928     Document Type: Article

References (65)

1. Gatzoulis MA, Barst R, Fineman J, Galie N. Eisenmenger syndrome and pulmonary arterial hypertension in adults with congenital heart disease. Curr Med Res Opin 2007; 23 (Suppl 2): S1-S7.
2. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in Patients with Primary Pulmonary Hypertension: Results of a National Prospective Registry. Annals Int Med 1991; 115: 343-349.
3. Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. Medical Therapy for Pulmonary Arterial Hypertension. Updated ACCP Evidence-Based Clinical Practice Guidelines. Chest 2007; 131: 1917-1928.
4. Humbert M, Nunes H, Sitbon O, Parent F, Herve P, Simonneau G. Risk factors for pulmonary arterial hypertension. Clin Chest Med 2001; 22: 459-475.
5. Recommendations on the management of pulmonary hypertension in clinical practice. Heart 2001; 86 (Suppl 1): I1-I13.
6. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351: 1425-1436.
7. Bowyer JJ, Busst CM, Denison DM, Shinebourne EA. Effect of long term oxygen treatment at home in children with pulmonary vascular disease. Br Heart J 1986; 55: 385-390.
8. Sandoval J, Aguirre JS, Pulido T, et al. Nocturnal oxygen therapy in patients with the Eisenmenger syndrome. Am J Respir Crit Care Med 2001; 164: 1682-1687.
9. Rich S, Seidlitz M, Dodin E, et al. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest 1998; 114: 787-792.
10. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: Natural history and the importance of thrombosis. Circulation 1984; 70: 580-587.
11. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327: 76-81.
12. Niwa K, Perloff JK, Kaplan S, Child JS, Miner PD. Eisenmenger syndrome in adults: Ventricular septal defect, truncus arteriosus, univentricular heart. J Am Coll Cardiol 1999; 34: 223-232.
13. Rich S. In: World Symposium on Primary pulmonary Hypertension; 1998; Evian, France; 1998.
14. Lockshin M, Tenedios F, Petri M, et al. Cardiac disease in the antiphospholipid syndrome: Recommendations for treatment. Committee consensus report. Lupus 2003; 12: 518-523.
15. Rosenzweig EB, Widlitz AC, Barst RJ. Pulmonary arterial hypertension in children. Pediatr Pulmonol 2004; 38: 2-22.
16. Gaine S. Pulmonary hypertension. Jama 2000; 284: 3160-3168.
17. Sitbon O, Humbert M, JaÔs X, et al. Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension. Circulation 2005; 111: 3105-3111.
18. Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992; 327: 70-75.
19. Adatia I, Haworth SG. Circulating endothelin in children with congenital heart disease. Br Heart J 1993; 69: 233-236.
20. Tuder RM, Cool CD, Geraci MW, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999; 159: 1925-1932.
21. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 334: 296-302.
22. Shapiro SM, Oudiz RJ, Cao T, et al. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol 1997; 30: 343-349.
23. McLaughlin VV, Genthner DE, Panella MM, Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998; 338: 273-277.
24. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: Prognostic factors and survival. J Am Coll Cardiol 2002; 40: 780-788.
25. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000; 132: 425-434.
26. McLaughlin VV, Genthner DE, Panella MM, Hess DM, Rich S. Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: A case series. Ann Intern Med 1999; 130: 730-733.
27. Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999; 99: 1858-1865.
28. McLaughlin VV, Gaine SP, Barst RJ, et al. Efficacy and safety of treprostinil: An epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol 2003; 41: 293-299.
29. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary hypertension. Am J Respir Crit Care Med 2002; 165: 1-5.
30. Higenbottam TW, Butt AY, Dinh-Xaun AT, Takao M, Cremona G, Akamine S. Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost. Heart 1998; 79: 175-179.
31. Higenbottam T, Butt AY, McMahon A, Westerbeck R, Sharples L. Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension. Heart 1998; 80: 151-155.
32. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347: 322-329.
33. Hoeper MM, Schwarze M, Ehlerding S, et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 2000; 342: 1866-1870.
34. Galie N, Humbert M, Vachiery JL, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: A randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002; 39: 1496-1502.
35. Barst RJ, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41: 2119-2125.
36. Clozel M. Effects of bosentan on cellular processes involved in pulmonary arterial hypertension: Do they explain the long-term benefit? Ann Med 2003; 35: 605-613.
37. Stewart DJ, Levy RD, Cernacek P, Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: Marker or mediator of disease? Ann Intern Med 1991; 114: 464-469.
38. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993; 328: 1732-1739.
39. Vancheeswaran R, Magoulas T, Efrat G, et al. Circulating endothelin-1 levels in systemic sclerosis subsets - a marker of fibrosis or vascular dysfunction? J Rheumatol 1994; 21: 1838-1844.
40. Jia B, Zhang S, Chen Z, et al. Plasma endothelin 1 concentrations in children with congenital heart defects. Minerva Pediatr 1998; 50: 99-103.
41. Allen SW, Chatfield BA, Koppenhafer SA, Schaffer MS, Wolfe RR, Abman SH. Circulating immunoreactive endothelin-1 in children with pulmonary hypertension. Association with acute hypoxic pulmonary vasoreactivity. Am Rev Respir Dis 1993; 148: 519-522.
42. Lutz J, Gorenflo M, Habighorst M, Vogel M, Lange PE, Hocher B. Endothelin-1- and endothelin-receptors in lung biopsies of patients with pulmonary hypertension due to congenital heart disease. Clin Chem Lab Med 1999; 37: 423-428.
43. Rubens C, Ewert R, Halank M, et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest 2001; 120: 1562-1569.
44. Galiè N, Grigioni F, Bacchi-Reggiani L, et al. Relation of endothelin-1 to survival in patients with primary pulmonary hypertension. Eur J Clin Invest 1996; 26 (Supp 1): 273.
45. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: A randomised placebo-controlled study. Lancet 2001; 358: 1119-1123.
46. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903.
47. McLaughlin VV, Sitbon O, Badesch DB, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005; 25: 244-249.
48. Galiè N, Beghetti M, Gatzoulis MA, et al. Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators. Bosentan therapy in patients with Eisenmenger syndrome: A multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006; 114: 48-54.
49. Barst RJ, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 169: 441-447.
50. Barst RJ, Langleben D, Badesch D, et al. STRIDE-2 Study Group. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006; 47: 2056-2059.
51. Oudiz R, Torres F, Frost A, et al. ARIES-1: A placebo-controlled efficacy and safety study of ambrisentan in patients with pulmonary arterial hypertension. Chest 2006; 130: 121S.
52. Olschewski H, Galie N, Ghofrani HA, et al. Ambrisentan improves exercise capacity and time to clinical worsening in patients with pulmonary arterial hypertension: Results of the ARIES-2 study. Proc Am Thorac Soc 2006; 3: A728.
53. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327: 524-526.
54. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995; 333: 214-221.
55. Kuhn KP, Wickersham NE, Robbins IM, Byrne DW. Acute effects of sildenafil in patients with primary pulmonary hypertension receiving epoprostenol. Exp Lung Res 2004; 30: 135-145.
56. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension. N Engl J Med 2005; 353: 2148-2157.
57. Wilkens H, Guth A, Konig J, et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001; 104: 1218-1222.
58. Ghofrani HA, Wiedemann R, Rose F, et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 2002; 136: 515-522.
59. Kothari SS, Duggal B. Chronic oral sildenafil therapy in severe pulmonary artery hypertension. Indian Heart J 2002; 54: 404-409.
60. Simonneau G, Rubin LJ, Galie N, et al. PACES Study Group. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: A randomized trial. Ann Intern Med 2008; 149: 521-530.
61. Nihill MR, O'Laughlin MP, Mullins CE. Effects of atrial septostomy in patients with terminal cor pulmonale due to pulmonary vascular disease. Cathet Cardiovasc Diagn 1991; 24: 166-172.
62. Kerstein D, Levy PS, Hsu DT, Hordof AJ, Gersony WM, Barst RJ. Blade balloon atrial septostomy in patients with severe primary pulmonary hypertension. Circulation 1995; 91: 2028-2035.
63. Sandoval J, Gaspar J, Pulido T, et al. Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment. J Am Coll Cardiol 1998; 32: 297-304.
64. Blanc J, Vouhé P, Bonnet D. Potts shunt in patients with pulmonary hypertension. N Engl J Med 2004; 350: 623.
65. Hopkins WE, Ochoa LL, Richardson GW, Trulock EP. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. J Heart Lung Transplant 1996; 15 (1 pt 1): 100-105.